Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013
Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma Source: International Congress 2016 – Phenotyping asthma Year: 2016
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015
COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Asthma symptoms, SABA use, and lung function before and after a moderate or severe exacerbation Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Midrange-proadrenomedullin in stable state predicts severe exacerbation of COPD Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007
Asthma exacerbations in relation to severe asthma Source: Eur Respir Mon 2011; 51: 120-129 Year: 2011
Why is it important to consider (sub)phenotypes of asthma and COPD? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Evaluation and management of difficult-to-control asthma Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007
Inflammation biomarkers of lung tissue damage in acute exacerbation of COPD patients Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013
Does inflammation decrease after recovery from severe exacerbation of COPD? Source: Eur Respir J 2005; 26: Suppl. 49, 53s Year: 2005
A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014
Inflammatory serum profiles are consistent across independent exacerbations in COPD patients with a history of frequent exacerbations Source: International Congress 2015 – COPD: interesting notes Year: 2015